scholarly journals Motion - Colonoscopic Surveillance is more Cost Effective than Colectomy in Patients with Ulcerative Colitis: Arguments Against the Motion

2003 ◽  
Vol 17 (2) ◽  
pp. 122-124 ◽  
Author(s):  
Anders Ekbom

There are insufficient data upon which to base recommendations about surveillance colonoscopy and prophylactic colectomy for the prevention of colorectal cancer in patients with ulcerative colitis. Case series, analyses of intermediate results and extrapolations from other patient groups do not constitute reliable evidence. Available studies are susceptible to several biases: the ’healthy worker’ effect, surveillance bias and selection bias. Patients who are enrolled in surveillance programs are more likely to be thoroughly evaluated beforehand, are more likely to be given a diagnosis of dysplasia or neoplasm even when asymptomatic and are more likely to comply with medical treatment, including maintenance anti-inflammatory medication. Comparisons of the rates of neoplasia or death between surveyed and nonsurveyed patients are, therefore, of questionable validity. Prophylactic colectomy, unlike surveillance colonoscopy, prevents death from colorectal cancer. Moreover, it is difficult to keep patients in surveillance programs, and those who withdraw from programs appear to be at high risk of developing cancer. Prophylactic colectomy should be strongly considered for patients with dysplasia, sclerosing cholangitis, longstanding pancolitis (especially if it began early in life) or a positive family history of colorectal cancer. This procedure is underused in clinical practice and is a good alternative to colonoscopic surveillance in high risk patients.

2003 ◽  
Vol 17 (2) ◽  
pp. 119-121 ◽  
Author(s):  
Bret A Lashner

Patients with ulcerative colitis (UC) are at increased risk for colorectal cancer (CRC), especially those with longstanding disease, pancolitis or primary sclerosing cholangitis. The incidence of colitis- associated cancer is increasing, and the mortality rates from CRC are higher in UC patients than in the general population. Case control studies have demonstrated that surveillance colonoscopy reduces the risk of dying from CRC. A well conducted decision analysis found that surveillance colonoscopy decreases cancer-related mortality and increases life expectancy. The results with surveillance programs were almost as good as with prophylactic colectomy. A subsequent cost effectiveness analysis using the same model found that, compared with a policy of no surveillance, colonoscopic surveillance was more effective at preventing death from CRC and was less costly. The best strategy appears to be to perform colonoscopies every three years. The analysis also showed that colectomy should be recommended in patients with low-grade dysplasia. Patients at very high risk for CRC should undergo yearly colonoscopy, and patients who are concerned about the limitations of this technique should be offered prophylactic colectomy.


2019 ◽  
Vol 114 (3) ◽  
pp. 483-489 ◽  
Author(s):  
Keisuke Hata ◽  
Hiroyuki Anzai ◽  
Hiroki Ikeuchi ◽  
Kitaro Futami ◽  
Kouhei Fukushima ◽  
...  

1993 ◽  
Vol 105 (2) ◽  
pp. 418-424 ◽  
Author(s):  
Paul M. Choi ◽  
F.Warren Nugent ◽  
David J. Schoetz ◽  
Mark L Silverman ◽  
Rodger C. Haggitt

2017 ◽  
Vol 153 (6) ◽  
pp. 1634-1646.e8 ◽  
Author(s):  
Yuji Toiyama ◽  
Yoshinaga Okugawa ◽  
Koji Tanaka ◽  
Toshimitsu Araki ◽  
Keiichi Uchida ◽  
...  

Gut ◽  
1998 ◽  
Vol 42 (5) ◽  
pp. 711-714 ◽  
Author(s):  
P Karlén ◽  
D Kornfeld ◽  
O Broström ◽  
R Löfberg ◽  
P-G Persson ◽  
...  

Background—Colonoscopic surveillance is a standard procedure in many patients with long standing, extensive ulcerative colitis (UC), in order to avoid death from colorectal cancer. No conclusive proof of its benefits has been presented however.Aims—To evaluate the association between colonoscopic surveillance and colorectal cancer mortality in patients with UC.Patients—A population based, nested case control study comprising 142 patients with a definite UC diagnosis, derived from a study population of 4664 patients with UC, was conducted.Methods—Colonoscopic surveillance in all patients with UC who had died from colorectal cancer after 1975 was compared with that in controls matched for age, sex, extent, and duration of the disease. Information on colonoscopic surveillance was obtained from the medical records.Results—Two of 40 patients with UC and 18 of 102 controls had undergone at least one surveillance colonoscopy (relative risk (RR) 0.29, 95% confidence interval 0.06 to 1.31). Twelve controls but only one patient with UC had undergone two or more surveillance colonoscopies (RR 0.22, 95% confidence interval 0.03 to 1.74), indicating a protective dose response relation.Conclusion—Colonoscopic surveillance may be associated with a decreased risk of death from colorectal cancer in patients with long standing UC.


2016 ◽  
Vol 14 (3) ◽  
pp. 264 ◽  
Author(s):  
Sawan Bopanna ◽  
Maitreyee Roy ◽  
Prasenjit Das ◽  
S Dattagupta ◽  
V Sreenivas ◽  
...  

1990 ◽  
Vol 4 (7) ◽  
pp. 378-383 ◽  
Author(s):  
RH Riddell

Patients at highest risk for developing cancer in ulcerative colitis are those with ‘extensive’ or total involvement of the large bowel who have had the disease for at least seven years. Dysplasia is used as a marker bur has many problems including those of sampling, reproducibility and management. The risk in patients with colitis is unclear particularly in those with left-sided or distal ulcerative colitis. In countries at high risk from colorectal cancer about 4 to 6% of the population can be expected to develop this disease. It is assumed that surveillance will reduce the mortality from colorectal cancer, although the evidence that this is happening is very limited. Cancers which are resected but from which the patient survives are an acceptable outcome, although less so in theory, as survival is to a certain extent fortuitous. Many surveillance studies include patients who have both developed and died from carcinoma. Surveillance also assumes that cancers can be detected before they have become lethal, or that a marker such as the presence of dysplasia precedes all carcinomas for a long enough period of time to be detectable. Considerable question has been raised as to whether dysplasia is both endoscopically detectable and morphologically identifiable. Surveillance is based on the principle that carcinoma arises from a cancerous lesion, and that the identification of dysplasia and excision of the large bowel in these patients prevents subsequent death from disseminated carcinoma. Conversely, patients with quiescent disease and no dysplasia could be followed and not subjected to unnecessary colectomy. There is currently no ‘best’ way of managing patients with colitis who are at risk for developing carcinoma. Routine follow-up of patients relies heavily on colonoscopy with multiple biopsies. Controversy continues regarding the management of dysplastic biopsies because there are relatively few data regarding the likelihood of an underlying invasive carcinoma on which to base a rational decision. The notion that all patients must be managed on an individual basis, guarantees that data remain difficult to obtain. The presence of a dysplasia-associated lesion or mass are high risk factors for carcinoma. Dysplasia is frequently confined to small areas of the mucosa causing major sampling problems for the endoscopist both in detection and if confirmation by re-endoscopy is proposed. The finding of aneuploidy as a marker for both dysplasia and carcinoma may prove useful in the detection of patients at greatest risk.


Sign in / Sign up

Export Citation Format

Share Document